AngioDynamics (NASDAQ:ANGO) Cut to “Strong Sell” at Zacks Research

Zacks Research cut shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a strong sell rating in a research report report published on Thursday morning,Zacks.com reports.

Several other equities analysts have also commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Canaccord Genuity Group lifted their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Finally, HC Wainwright boosted their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics currently has an average rating of “Hold” and an average target price of $19.50.

AngioDynamics Trading Down 4.5%

Shares of NASDAQ ANGO opened at $13.51 on Thursday. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $15.19. The company has a market cap of $558.37 million, a P/E ratio of -15.53 and a beta of 0.34. The stock has a fifty day moving average price of $12.24 and a 200 day moving average price of $11.35.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. The company had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts forecast that AngioDynamics will post -0.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Kotler Kevin acquired a new position in shares of AngioDynamics in the 4th quarter valued at approximately $21,997,000. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics during the fourth quarter worth approximately $17,978,000. UBS Group AG grew its position in shares of AngioDynamics by 83.6% during the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after buying an additional 501,881 shares in the last quarter. Millennium Management LLC increased its stake in shares of AngioDynamics by 28.1% in the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after buying an additional 393,682 shares during the last quarter. Finally, Nuveen LLC increased its stake in shares of AngioDynamics by 40.5% in the fourth quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock worth $16,629,000 after buying an additional 373,110 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.